T 1996/17 (Exendins for treating type II diabetes/AMYLIN) of 11.10.2021
- European Case Law Identifier
- ECLI:EP:BA:2021:T199617.20211011
- Date of decision
- 11 October 2021
- Case number
- T 1996/17
- Petition for review of
- -
- Application number
- 06801867.0
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Exendin for treating diabetes and reducing body weight
- Applicant name
- Amylin Pharmaceuticals, LLC
AstraZeneca Pharmaceuticals LP - Opponent name
- PHARMATHEN S.A.
Glaxo Group Limited
PENTAFARMA, Sociedade Técnico-Medicinal, SA
COOLEY LLP
Generics [UK] Ltd (trading as Mylan)
Teva Pharmaceutical Industries Ltd. - Board
- 3.3.04
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 123(3)Rules of procedure of the Boards of Appeal 2020 Art 013(2)
- Keywords
- Amendments - broadening of claim (yes)
Amendment after summons - exceptional circumstances (no)
Amendment after summons - cogent reasons (no) - Catchword
- -
- Cited cases
- -
- Citing cases
- T 2034/21
Order
For these reasons it is decided that:
The appeal is dismissed.